ASCO 2023 – Bicara eyes head and neck niche

[cafead]

via Bicara raised $108m in March on the back of encouraging early data on BCA101, a bispecific antibody that hits both EGFR and TGF-beta. With strong responses now confirmed in head and neck cancer, and a registrational trial potentially on the horizon, the group is already thinking about its next financing.

article source